On 5th August, WeTrade Group Inc. announced a strategic partnership with Jiqing Biomedical Technology Co. Ltd. (Jiqing). The two companies plan to produce and provide exclusive sale channels for monkeypox virus test kits and antigen tests worldwide, aiming to develop domestic and international markets.

This collaboration also means that WeTrade Group has started to cover the medical industry. Compared with the international advanced system, China's medical industry chain is relatively in the beginning stage, and most of the medical enterprises are small in scale and have limited competitiveness in the process of "operating globally". During the pandemic, the antigen self-test kit developed by Jiqing was fully approved by EU, and now Jiqing antigen products have obtained product registration certificates from dozens of countries such as Thailand FDA, UK MHRA, EU CE, Germany Bfarm, Netherlands CIBG, Malaysia MDA, Cambodia, Indonesia, Philippines, etc.

The products are exported to more than 60 countries and regions internationally. The rapid spread of monkeypox has been declared as a public health emergency in the United States on 4th August. To help prevent and control the epidemic and detect the monkeypox infection cases, the bio research and development team of Jiqing has urgently developed two monkeypox virus detection kits: nucleic acid test (RT-LAMP) and antigen test (colloidal gold technique).